Literature DB >> 15537676

Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study.

G D Honey1, R A E Honey, C O'Loughlin, S R Sharar, D Kumaran, J Suckling, D K Menon, C Sleator, E T Bullmore, P C Fletcher.   

Abstract

The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine produces episodic memory deficits. We used functional magnetic resonance imaging to characterize the effects of ketamine on frontal and hippocampal responses to memory encoding and retrieval in healthy volunteers using a double-blind, placebo-controlled, randomized, within-subjects comparison of two doses of intravenous ketamine. Dissociation of the effects of ketamine on encoding and retrieval processes was achieved using two study-test cycles: in the first, items were encoded prior to drug infusion and retrieval tested, during scanning, on drug; in the second, encoding was scanned on drug, and retrieval tested once ketamine plasma levels had declined. We additionally determined the interaction of ketamine with the depth of processing that occurred at encoding. A number of effects upon task-dependent activations were seen. Overall, our results suggest that left frontal activation is augmented by ketamine when elaborative semantic processing is required at encoding. In addition, successful encoding on ketamine is supplemented by additional non-verbal processing that is incidental to task demands. The effects of ketamine at retrieval are consistent with impaired access to accompanying contextual features of studied items. Our findings show that, even when overt behaviour is unimpaired, ketamine has an impact upon the recruitment of key regions in episodic memory task performance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537676      PMCID: PMC3838947          DOI: 10.1093/cercor/bhh176

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  60 in total

1.  Brain activity during memory retrieval. The influence of imagery and semantic cueing.

Authors:  P C Fletcher; T Shallice; C D Frith; R S Frackowiak; R J Dolan
Journal:  Brain       Date:  1996-10       Impact factor: 13.501

2.  Discrimination and response bias in memory: effects of depression severity and psychomotor retardation.

Authors:  G Brébion; M J Smith; D Widlocher
Journal:  Psychiatry Res       Date:  1997-05-05       Impact factor: 3.222

3.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.

Authors:  A Breier; A K Malhotra; D A Pinals; N I Weisenfeld; D Pickar
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

4.  Glutamate pharmacology and the treatment of schizophrenia: current status and future directions.

Authors:  C A Tamminga; H H Holcomb; X M Gao; A C Lahti
Journal:  Int Clin Psychopharmacol       Date:  1995-09       Impact factor: 1.659

5.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

6.  NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

Authors:  A K Malhotra; D A Pinals; H Weingartner; K Sirocco; C D Missar; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1996-05       Impact factor: 7.853

7.  Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).

Authors:  F X Vollenweider; K L Leenders; I Oye; D Hell; J Angst
Journal:  Eur Neuropsychopharmacol       Date:  1997-02       Impact factor: 4.600

8.  Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

Authors:  F X Vollenweider; K L Leenders; C Scharfetter; A Antonini; P Maguire; J Missimer; J Angst
Journal:  Eur Neuropsychopharmacol       Date:  1997-02       Impact factor: 4.600

9.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

Authors:  A C Lahti; H H Holcomb; D R Medoff; C A Tamminga
Journal:  Neuroreport       Date:  1995-04-19       Impact factor: 1.837

10.  Glutamate receptor dysfunction and schizophrenia.

Authors:  J W Olney; N B Farber
Journal:  Arch Gen Psychiatry       Date:  1995-12
View more
  39 in total

Review 1.  Neuroanatomical and neurochemical substrates of timing.

Authors:  Jennifer T Coull; Ruey-Kuang Cheng; Warren H Meck
Journal:  Neuropsychopharmacology       Date:  2010-07-28       Impact factor: 7.853

Review 2.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

Review 3.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

4.  High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors:  W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal:  Neural Plast       Date:  2010-02-18       Impact factor: 3.599

5.  Greater vulnerability to the amnestic effects of ketamine in males.

Authors:  Celia J A Morgan; Edward B Perry; Hyung-Sang Cho; John H Krystal; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

6.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.

Authors:  Frederick S Barrett; Theresa M Carbonaro; Ethan Hurwitz; Matthew W Johnson; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2018-07-30       Impact factor: 4.530

Review 7.  Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Authors:  Weili Zhu; Zengbo Ding; Yinan Zhang; Jie Shi; Kenji Hashimoto; Lin Lu
Journal:  Neurosci Bull       Date:  2016-11-22       Impact factor: 5.203

8.  Network oscillatory activity driven by context memory processing is differently regulated by glutamatergic and cholinergic neurotransmission.

Authors:  Adam M P Miller; Brendan J Frick; David M Smith; Jelena Radulovic; Kevin A Corcoran
Journal:  Neurobiol Learn Mem       Date:  2017-08-30       Impact factor: 2.877

9.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

10.  Effects of ketamine on brain function during smooth pursuit eye movements.

Authors:  M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Hum Brain Mapp       Date:  2016-11       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.